Condition: Type 1 Diabetes Mellitus · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The goal is to establish the effect of oral probiotic Desulfovibrio piger (D. piger) supplementation on immunological and metabolic parameters in individuals with longstanding type 1 diabetes with residual beta cell function. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x10 participants to measure effects of D. piger on parameters of systemic and intestinal inflammation and residual beta cell function.
This description comes directly from the study's public registry record.
Max Nieuwdorp, Prof. Dr. · +31 20-5669111 · m.nieuwdorp@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Diabeter Centrum Amsterdam | Amsterdam, Netherlands | Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07585994